Market Cap | 620.32M | P/E | - | EPS this Y | -9.00% | Ern Qtrly Grth | - |
Income | -162.1M | Forward P/E | -3.39 | EPS next Y | 38.10% | 50D Avg Chg | -2.00% |
Sales | 374k | PEG | 0.01 | EPS past 5Y | - | 200D Avg Chg | -15.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | -134.00% | 52W High Chg | -49.00% |
Recommedations | 2.70 | Quick Ratio | 0.83 | Shares Outstanding | 152.38M | 52W Low Chg | 13.00% |
Insider Own | 5.44% | ROA | -27.10% | Shares Float | 120.20M | Beta | 2.01 |
Inst Own | 45.40% | ROE | - | Shares Shorted/Prior | 17.22M/16.75M | Price | 4.85 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 2,589,375 | Target Price | 3.34 |
Oper. Margin | -42,211.23% | Earnings Date | Oct 31 | Volume | 1,415,031 | Change | 0.41% |
Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Canaccord Genuity | Buy | Sep 13, 24 |
Canaccord Genuity | Buy | Aug 14, 24 |
Chardan Capital | Buy | Aug 14, 24 |
Oppenheimer | Perform | Jun 7, 24 |
Canaccord Genuity | Buy | Jun 7, 24 |
Oppenheimer | Outperform | May 9, 24 |
Chardan Capital | Buy | May 8, 24 |
Oppenheimer | Outperform | Mar 6, 24 |
Chardan Capital | Buy | Mar 6, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Cloghessy Paula | See Remarks See Remarks | Oct 27 | Option | 0 | 9,418 | 48,588 | 10/31/23 | |
Cloghessy Paula | See Remarks See Remarks | Oct 27 | Sell | 1.35 | 2,904 | 3,920 | 45,684 | 10/31/23 |
Shaff Eric D. | CEO and President CEO and President | Oct 27 | Sell | 1.35 | 8,552 | 11,545 | 115,620 | 10/31/23 |
Shaff Eric D. | CEO and President CEO and President | Oct 27 | Option | 0 | 27,838 | 124,172 | 10/31/23 | |
Young Teresa L. | See Remarks See Remarks | Oct 27 | Sell | 1.35 | 2,907 | 3,924 | 8,454 | 10/31/23 |
Young Teresa L. | See Remarks See Remarks | Oct 27 | Option | 0 | 11,361 | 11,361 | 10/31/23 | |
Arkowitz David | Chief Financial Offi.. Chief Financial Officer | Oct 27 | Sell | 1.35 | 4,066 | 5,489 | 175,756 | 10/31/23 |
Arkowitz David | Chief Financial Offi.. Chief Financial Officer | Oct 27 | Option | 0 | 13,209 | 179,822 | 10/31/23 | |
DesRosier Thomas | Chief Legal Officer.. Chief Legal Officer and EVP | Oct 27 | Option | 0 | 13,501 | 118,047 | 10/31/23 | |
DesRosier Thomas | Chief Legal Officer.. Chief Legal Officer and EVP | Oct 27 | Sell | 1.35 | 4,156 | 5,611 | 113,891 | 10/31/23 |
Ege David S. | See Remarks See Remarks | Oct 27 | Sell | 1.35 | 4,066 | 5,489 | 66,991 | 10/31/23 |
Ege David S. | See Remarks See Remarks | Oct 27 | Option | 0 | 11,361 | 71,057 | 10/31/23 | |
von Moltke Lisa | See Remarks See Remarks | Oct 27 | Sell | 1.35 | 4,232 | 5,713 | 9,513 | 10/31/23 |
von Moltke Lisa | See Remarks See Remarks | Oct 27 | Option | 0 | 13,745 | 13,745 | 10/31/23 | |
Henn Matthew R. | See Remarks See Remarks | Oct 27 | Sell | 1.35 | 3,886 | 5,246 | 56,356 | 10/31/23 |
Henn Matthew R. | See Remarks See Remarks | Oct 27 | Option | 0 | 12,623 | 60,242 | 10/31/23 | |
Ege David S. | See Remarks See Remarks | Apr 27 | Sell | 5.19 | 7,038 | 36,527 | 59,696 | 05/01/23 |
Ege David S. | See Remarks See Remarks | Oct 27 | Sell | 7.93 | 5,012 | 39,745 | 46,734 | 10/31/22 |
Nutritional Health LTP Fund Ge... | 10% Owner 10% Owner | Jul 05 | Buy | 3.15 | 8,738,243 | 27,525,465 | 5,825,495 | 07/07/22 |